Company intelligence / Profile preview
Tonghua Jinma Pharmaceutical Group
Tonghua, Jilin, Chinathjm.cn ↗
- Ownership
- Private
- Employees
- ~1651
- Development stage
- Other
01
Overview
Tonghua Jinma's Alzheimer's drug 'amber octahydroaminoacridine tablet' has successfully completed Phase 3 and met its primary endpoint for mild and moderate Alzheimer's disease. The company also manufactures and markets a broad range of approved products including traditional Chinese medicines, biosynthetic drugs, live bacterial therapies, and peptide-based treatments for various indications.
- Therapeutic areas
- ImmunologyGastroenterologyNeurologyOtherEndocrinologyRheumatology
- Modalities
- Small moleculeBiologicPeptidesLive biotherapeutic product therapyTraditional Chinese medicine
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Tonghua Jinma Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tonghua Jinma Pharmaceutical Group.